2022 World Conference on Lung Cancer (ePosters)-EP14.05-007. A Study of the Best Reduction in Target Lesion Size and Treatment Duration in the Durvalumab plus Platinum-Etoposide Regimen for ES-SCLC

EP14.05-007. A Study of the Best Reduction in Target Lesion Size and Treatment Duration in the Durvalumab plus Platinum-Etoposide Regimen for ES-SCLC

Pdf Summary

Summary Not Available

Asset Subtitle

Kageaki Watanabe

Meta Tag

Speaker Kageaki Watanabe

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC